Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Data Shows 'Majority' of Patients in Liver Cancer Extension Study Have Stable Disease

Premium

Alnylam Pharmaceuticals this week announced data from a phase I extension study of its RNAi-based liver cancer therapy ALN-VSP, which showed the drug could control disease for more than six months in the majority of patients treated.

The findings include a complete response from an endometrial cancer patient with multiple liver metastases.

The extension study enrolled patients from a previous phase I trial who achieved stable disease after four months or longer of ALN-VSP treatment. Main objectives included continued evaluation of safety and tolerability and assessment of disease response.

Alnylam previously announced that it would only advance ALN-VSP into phase II testing with a partner, and that it expected to forge such a deal this year (GSN 5/10/2012).

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.